Nano-X Imaging director buys 50,000 ordinary shares

Nano-X Imaging Ltd. director Suesskind Dan S reported open-market purchases of a total of 50,000 Ordinary Shares on July 27, 2026, in two blocks of 25,000 shares at $0.94 and $0.92 per share.

Rhea-AI Filing Summary

Nano-X Imaging Ltd. director Suesskind Dan S reported open-market purchases of a total of 50,000 Ordinary Shares on July 27, 2026, in two blocks of 25,000 shares at $0.94 and $0.92 per share. The Rule 10b5-1 checkbox was not marked for these transactions.

He also reports outstanding stock options to acquire 12,505 shares at $64.6100, 50,000 shares at $17.6300, and 10,000 shares at $11.5200, with expirations between 2031 and 2033, plus time-vested RSUs granted in 2024 and 2025.

Insider Trade Summary

Net Buyer: 50,000 shares

Net Buy 7 txns

Insider Suesskind Dan S

Role Director

Bought 50,000 shs ($47K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares	25,000	$0.94	$24K
Purchase	Ordinary Shares	25,000	$0.92	$23K
holding	Stock Option (right to buy ordinary shares) F1, F4	--	--	--
holding	Stock Option (right to buy ordinary shares) F1, F5	--	--	--
holding	Stock Option (right to buy ordinary shares) F1, F6	--	--	--
holding	Ordinary Shares F1, F2	--	--	--
holding	Ordinary Shares F1, F3	--	--	--

Holdings After Transaction: Ordinary Shares — 75,336 shares (Direct); Stock Option (right to buy ordinary shares) — 72,505 contracts (Direct)

Footnotes (6)

1. F1. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
2. F2. The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person by the Issuer on December 10, 2024 and that vest and settle for underlying shares in twelve equal quarterly installments (each for 8.33% of the RSUs granted) such that by the three-year anniversary of the grant date (December 10, 2027) all underlying shares will be issued to the Reporting Person.
3. F3. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person by the Issuer on December 10, 2025 and that vest and settle for underlying shares in twelve equal quarterly installments (each for 8.33% of the RSUs granted) such that by the three-year anniversary of the grant date (December 10, 2028) all underlying shares will be issued to the Reporting Person.
4. F4. The options reported in this row were granted to the Reporting Person by the Issuer on February 9, 2021 and are fully vested and exercisable as of the date of this report.
5. F5. The options reported in this row were granted to the Reporting Person by the Issuer on December 28, 2022 and are fully vested and exercisable as of the date of this report.
6. F6. The options reported in this row were granted to the Reporting Person by the Issuer on December 31, 2023 and vest and become exercisable in 16 equal installments of 6.25% each on each three-month anniversary of the date of approval of the grant by the Issuer's Board of Directors (i.e., August 14, 2023), such that all options reported in this row will be exercisable on the four-year anniversary of that grant approval date (August 14, 2027).

Key Figures

Shares purchased at $0.9400: 25,000 shares at $0.9400 per share Shares purchased at $0.9200: 25,000 shares at $0.9200 per share Total shares purchased: 50,000 Ordinary Shares +3 more

6 metrics

Shares purchased at $0.9400 25,000 shares at $0.9400 per share Open-market purchase of Ordinary Shares on July 27, 2026

Shares purchased at $0.9200 25,000 shares at $0.9200 per share Second open-market purchase of Ordinary Shares on July 27, 2026

Total shares purchased 50,000 Ordinary Shares Aggregate net-buy Ordinary Share purchases reported for July 27, 2026

Option exercise price 2031 grant $64.6100 per share Stock option over 12,505 underlying Ordinary Shares expiring February 9, 2031

Option exercise price 2032 grant $17.6300 per share Stock option over 50,000 underlying Ordinary Shares expiring December 28, 2032

Option exercise price 2033 grant $11.5200 per share Stock option over 10,000 underlying Ordinary Shares expiring December 31, 2033

Key Terms

restricted share units ("RSUs"), fully vested and exercisable, three-year anniversary of the grant date, equal quarterly installments

4 terms

restricted share units ("RSUs") financial

"shares underlying restricted share units ("RSUs") that were granted to the Reporting Person"

fully vested and exercisable financial

"options reported in this row were granted ... and are fully vested and exercisable as of the date"

three-year anniversary of the grant date financial

"such that by the three-year anniversary of the grant date ... all underlying shares will be issued"

equal quarterly installments financial

"vest and settle for underlying shares in twelve equal quarterly installments (each for 8.33% of the RSUs granted)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider buying did Nano-X Imaging (NNOX) disclose for Suesskind Dan S?

Suesskind Dan S, a director of Nano-X Imaging, reported purchasing a total of 50,000 Ordinary Shares on July 27, 2026, in two separate 25,000-share open-market transactions at $0.94 and $0.92 per share, increasing his direct equity exposure.

At what prices did the Nano-X Imaging (NNOX) director buy shares?

The director bought 25,000 Ordinary Shares at $0.94 per share and another 25,000 Ordinary Shares at $0.92 per share on July 27, 2026. Both transactions are reported as open-market or private purchases and classified as direct ownership.

Were the NNOX insider share purchases made under a Rule 10b5-1 trading plan?

The Rule 10b5-1 checkbox is not marked, indicating these purchases are not reported as trades under a Rule 10b5-1 plan. This suggests the transactions were discretionary rather than executed under a pre-arranged trading program.

What stock options does the Nano-X Imaging (NNOX) director hold after these transactions?

He holds stock options over 12,505 shares at $64.6100 expiring February 9, 2031, 50,000 shares at $17.6300 expiring December 28, 2032, and 10,000 shares at $11.5200 expiring December 31, 2033, all reported as directly owned awards.

What RSU awards are reported for the Nano-X Imaging (NNOX) director?

Footnotes describe RSUs granted on December 10, 2024 and December 10, 2025. Each grant vests in twelve equal quarterly installments of 8.33% so that all underlying shares are issued by the respective three-year anniversaries in December 2027 and December 2028.

What is Suesskind Dan S’s role at Nano-X Imaging (NNOX)?

Suesskind Dan S is reported as a director of Nano-X Imaging Ltd., with no officer position and not flagged as a more-than-10% shareholder. The reported Ordinary Share purchases and equity awards reflect his personal director-level holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/29/2026 - 07:40 AM Accepted by SEC EDGAR 07/29/2026 - 07:40 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Suesskind Dan S

(Last) (First) (Middle)

C/O NANO-X IMAGING LTD., OFER TECH PARK

94 SHLOMO SHMELTZER ROAD

(Street)

PETACH TIKVA 4970602

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nano-X Imaging Ltd. [ NNOX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	07/27/2026		P		25,000	A	$0.94	25,000	D
Ordinary Shares	07/27/2026		P		25,000	A	$0.92	50,000	D
Ordinary Shares(1)								7,792(2)	D
Ordinary Shares(1)								17,544(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy ordinary shares)(1)	$64.61							(4)	02/09/2031	Ordinary Shares	12,505		12,505	D
Stock Option (right to buy ordinary shares)(1)	$17.63							(5)	12/28/2032	Ordinary Shares	50,000		50,000	D
Stock Option (right to buy ordinary shares)(1)	$11.52							(6)	12/31/2033	Ordinary Shares	10,000		10,000	D

Explanation of Responses:

1. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.

2. The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person by the Issuer on December 10, 2024 and that vest and settle for underlying shares in twelve equal quarterly installments (each for 8.33% of the RSUs granted) such that by the three-year anniversary of the grant date (December 10, 2027) all underlying shares will be issued to the Reporting Person.

3. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person by the Issuer on December 10, 2025 and that vest and settle for underlying shares in twelve equal quarterly installments (each for 8.33% of the RSUs granted) such that by the three-year anniversary of the grant date (December 10, 2028) all underlying shares will be issued to the Reporting Person.

4. The options reported in this row were granted to the Reporting Person by the Issuer on February 9, 2021 and are fully vested and exercisable as of the date of this report.

5. The options reported in this row were granted to the Reporting Person by the Issuer on December 28, 2022 and are fully vested and exercisable as of the date of this report.

6. The options reported in this row were granted to the Reporting Person by the Issuer on December 31, 2023 and vest and become exercisable in 16 equal installments of 6.25% each on each three-month anniversary of the date of approval of the grant by the Issuer's Board of Directors (i.e., August 14, 2023), such that all options reported in this row will be exercisable on the four-year anniversary of that grant approval date (August 14, 2027).

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Marina Gofman Feler, attorney-in-fact	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)